CN102459227B - Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 - Google Patents

Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 Download PDF

Info

Publication number: CN102459227B
Authority: CN; China
Prior art keywords: alkyl; phenyl; methyl; prepared; azetidine
Prior art date: 2009-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN201080027641.6A

Other languages

English (en)

Chinese (zh)

Other versions

CN102459227A (zh

Inventor

张旭庆

H·R·赫夫奈格尔

侯翠玢

D·L·约翰森

隋治华

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-17

Filing date

2010-04-15

Publication date

2014-08-20

2010-04-15 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2012-05-16 Publication of CN102459227A publication Critical patent/CN102459227A/zh

2014-08-20 Application granted granted Critical

2014-08-20 Publication of CN102459227B publication Critical patent/CN102459227B/zh

Status Expired - Fee Related legal-status Critical Current

2030-04-15 Anticipated expiration legal-status Critical

Links

0 C*CC(C)NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O Chemical compound C*CC(C)NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O 0.000 description 1
FYTMPPOAWMMTGA-UHFFFAOYSA-N CC(C)(C)OC(Nc(cc1)ccc1C(CC1)=CCC1=O)=O Chemical compound CC(C)(C)OC(Nc(cc1)ccc1C(CC1)=CCC1=O)=O FYTMPPOAWMMTGA-UHFFFAOYSA-N 0.000 description 1
DUPKTFVNPHZWNC-UHFFFAOYSA-N CC(C)(C)OC(Nc1cccc(C(CC2)(CCC22OCCO2)O)c1)=O Chemical compound CC(C)(C)OC(Nc1cccc(C(CC2)(CCC22OCCO2)O)c1)=O DUPKTFVNPHZWNC-UHFFFAOYSA-N 0.000 description 1
RVGRTRHVBFCARF-UHFFFAOYSA-N CC(C)(C)OC(Nc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)O)c1)=O Chemical compound CC(C)(C)OC(Nc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)O)c1)=O RVGRTRHVBFCARF-UHFFFAOYSA-N 0.000 description 1
FHENRZKRAUSKEY-ARLHGKGLSA-N CC(CC[C@@H](C)N(C1)CC1NC(CN)=O)C1=CC=CCC1 Chemical compound CC(CC[C@@H](C)N(C1)CC1NC(CN)=O)C1=CC=CCC1 FHENRZKRAUSKEY-ARLHGKGLSA-N 0.000 description 1
TWTISSNNQCPARJ-UHFFFAOYSA-N CCOC(c1cccc(C(CC2)CCC2=O)c1)=O Chemical compound CCOC(c1cccc(C(CC2)CCC2=O)c1)=O TWTISSNNQCPARJ-UHFFFAOYSA-N 0.000 description 1
OUWPXYDIJLVUSG-UHFFFAOYSA-N COc1cc(C(CC2)(CCC2=O)O)ccc1 Chemical compound COc1cc(C(CC2)(CCC2=O)O)ccc1 OUWPXYDIJLVUSG-UHFFFAOYSA-N 0.000 description 1
XUXGRGHZAIOCSD-UHFFFAOYSA-N COc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)N)c1 Chemical compound COc1cccc(C(CC2)(CCC2N(C2)CC2NC(CNC(c2cc(C(F)(F)F)ccc2)=O)=O)N)c1 XUXGRGHZAIOCSD-UHFFFAOYSA-N 0.000 description 1
YODHYTBRRINSKP-UHFFFAOYSA-N COc1ccccc1C(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=C)=O)O Chemical compound COc1ccccc1C(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=C)=O)O YODHYTBRRINSKP-UHFFFAOYSA-N 0.000 description 1
ZRUKZXVNNVHEBW-UHFFFAOYSA-N C[n]1c(cc(C(CC2)(CCC2=O)O)cc2)c2nc1 Chemical compound C[n]1c(cc(C(CC2)(CCC2=O)O)cc2)c2nc1 ZRUKZXVNNVHEBW-UHFFFAOYSA-N 0.000 description 1
COHHDKBOPDVULP-UHFFFAOYSA-N Cc1ccc(C(CC2)(CCC2=O)O)cc1 Chemical compound Cc1ccc(C(CC2)(CCC2=O)O)cc1 COHHDKBOPDVULP-UHFFFAOYSA-N 0.000 description 1
FREHTPKNPMUSMK-UHFFFAOYSA-N N#Cc1cc(C(CC2)=CCC2=O)ccc1 Chemical compound N#Cc1cc(C(CC2)=CCC2=O)ccc1 FREHTPKNPMUSMK-UHFFFAOYSA-N 0.000 description 1
JXNHEUAANNGFFV-UHFFFAOYSA-N NC(CC1)(CCC1=O)c1ccccc1 Chemical compound NC(CC1)(CCC1=O)c1ccccc1 JXNHEUAANNGFFV-UHFFFAOYSA-N 0.000 description 1
VZQQLYFMKYCMQZ-UHFFFAOYSA-N O=C(CC1)CC=C1c(cc1)ccc1N=O Chemical compound O=C(CC1)CC=C1c(cc1)ccc1N=O VZQQLYFMKYCMQZ-UHFFFAOYSA-N 0.000 description 1
LIDGWINURFOALA-UHFFFAOYSA-N O=C(CNC(c(cc1)cc(C(F)(F)F)c1F)=O)NC1CNC1 Chemical compound O=C(CNC(c(cc1)cc(C(F)(F)F)c1F)=O)NC1CNC1 LIDGWINURFOALA-UHFFFAOYSA-N 0.000 description 1
GRIUVLWWKAQKDF-UHFFFAOYSA-N O=C(CNC(c1cc(C(F)(F)F)ccc1)=O)NC(C1)CN1C(CC1)CCC1c1ccc(CCN2)c2c1 Chemical compound O=C(CNC(c1cc(C(F)(F)F)ccc1)=O)NC(C1)CN1C(CC1)CCC1c1ccc(CCN2)c2c1 GRIUVLWWKAQKDF-UHFFFAOYSA-N 0.000 description 1
WEMZPTVFMJNMRK-UHFFFAOYSA-N OC(CC1)(CCC1=O)c(cc1)ccc1Cl Chemical compound OC(CC1)(CCC1=O)c(cc1)ccc1Cl WEMZPTVFMJNMRK-UHFFFAOYSA-N 0.000 description 1
JAVULHNIYKQECV-UHFFFAOYSA-N OC(CC1)(CCC1=O)c1cccc(O)c1 Chemical compound OC(CC1)(CCC1=O)c1cccc(O)c1 JAVULHNIYKQECV-UHFFFAOYSA-N 0.000 description 1
CJRVNLPYFHEJPE-UHFFFAOYSA-N OC(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O)c(cc1)ccc1O Chemical compound OC(CC1)(CCC1N(C1)CC1NC(CNC(c1cc(C(F)(F)F)ccc1)=O)=O)c(cc1)ccc1O CJRVNLPYFHEJPE-UHFFFAOYSA-N 0.000 description 1
PRNCENABYSAGEY-UHFFFAOYSA-N Oc(cc1)ccc1C(CC1)=CCC1=O Chemical compound Oc(cc1)ccc1C(CC1)=CCC1=O PRNCENABYSAGEY-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Oncology (AREA)
Hematology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

CN201080027641.6A 2009-04-17 2010-04-15 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 Expired - Fee Related CN102459227B (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US17030709P	2009-04-17	2009-04-17
US61/170,307		2009-04-17
US61/170307		2009-04-17
PCT/US2010/031265 WO2010121046A1 (en)	2009-04-17	2010-04-15	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

Publications (2)

Publication Number	Publication Date
CN102459227A CN102459227A (zh)	2012-05-16
CN102459227B true CN102459227B (zh)	2014-08-20

Family

ID=42167720

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201080027641.6A Expired - Fee Related CN102459227B (zh)	2009-04-17	2010-04-15	Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂

Country Status (14)

Country	Link
US (2)	US20100267689A1 (2)
EP (1)	EP2419419B1 (2)
JP (1)	JP5675773B2 (2)
KR (1)	KR20120006544A (2)
CN (1)	CN102459227B (2)
AR (1)	AR076328A1 (2)
AU (1)	AU2010236346B2 (2)
BR (1)	BRPI1016189A2 (2)
CA (1)	CA2758934A1 (2)
ES (1)	ES2528625T3 (2)
MX (1)	MX2011010964A (2)
NZ (1)	NZ595432A (2)
TW (1)	TW201102377A (2)
WO (1)	WO2010121046A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2011006226A (es)	2008-12-10	2011-06-24	Janssen Pharmaceutica Nv	Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol del receptor 2 de citocina quimioatrayente.
TW201105649A (en) *	2009-04-16	2011-02-16	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
CN102459226B (zh)	2009-04-17	2014-09-17	詹森药业有限公司	Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
EP2419419B1 (en)	2009-04-17	2014-12-03	Janssen Pharmaceutica NV	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
TW201211027A (en) *	2010-06-09	2012-03-16	Janssen Pharmaceutica Nv	Cyclohexyl-azetidinyl antagonists of CCR2
US8518969B2 (en)	2010-06-17	2013-08-27	Janssen Pharmaceutica Nv	Cyclohexyl-azetidinyl antagonists of CCR2
US20140329809A1 (en)	2011-10-28	2014-11-06	Galderma Research & Development	New leukocyte infiltrate markers for rosacea and uses thereof
EP2780015B1 (en)	2011-11-18	2017-01-04	Heptares Therapeutics Limited	Muscarinic m1 receptor agonists
DK2785710T3 (en) *	2011-12-01	2017-12-04	Chemocentryx Inc	SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR (4) - ANTAGONISTS
JP5977349B2 (ja)	2012-06-15	2016-08-24	田辺三菱製薬株式会社	芳香族複素環化合物
GB201404922D0 (en)	2014-03-19	2014-04-30	Heptares Therapeutics Ltd	Pharmaceutical compounds
DK3209655T3 (da)	2014-10-24	2020-09-28	Landos Biopharma Inc	Lanthioninsyntease C-lignende 2-baserede Therapeutica
ES2764840T3 (es)	2015-01-28	2020-06-04	Univ Bordeaux	Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
DK3297438T3 (da)	2015-05-21	2022-01-17	Chemocentryx Inc	Ccr2-modulatorer
GB201513743D0 (en)	2015-08-03	2015-09-16	Heptares Therapeutics Ltd	Muscarinic agonists
GB201519352D0 (en)	2015-11-02	2015-12-16	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201617454D0 (en)	2016-10-14	2016-11-30	Heptares Therapeutics Limited	Pharmaceutical compounds
US10259787B2 (en)	2016-10-14	2019-04-16	Heptares Therapeutics Limited	Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
CA3293051A1 (en)	2017-09-25	2026-03-02	Chemocentryx, Inc.	Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
KR20200090873A (ko)	2017-11-30	2020-07-29	란도스 바이오파마, 인크.	란티오닌 c-유사 단백질 2 리간드 및 이와 함께 제조된 세포를 이용한 치료법
CN112105353B (zh)	2018-01-08	2024-04-19	凯莫森特里克斯股份有限公司	Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en)	2018-01-08	2019-09-05	Chemocentryx, Inc.	Methods of treating solid tumors with ccr2 antagonists
GB201810239D0 (en)	2018-06-22	2018-08-08	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819960D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB201819961D0 (en)	2018-12-07	2019-01-23	Heptares Therapeutics Ltd	Pharmaceutical compounds
GB202020191D0 (en)	2020-12-18	2021-02-03	Heptares Therapeutics Ltd	Pharmaceutical compounds
CN110028395A (zh) *	2019-05-29	2019-07-19	宁夏中星显示材料有限公司	一种4-(4-羟基苯基)环己酮的制备方法
KR20230026522A (ko)	2019-12-20	2023-02-24	란도스 바이오파마, 인크.	란티오닌 c-유사 단백질 2 리간드, 이로 제조된 세포, 및 이를 사용하는 치료법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030004151A1 (en) *	2000-12-20	2003-01-02	Robert Cherney	Cyclic derivatives as modulators of chemokine receptor activity
CN1741994A (zh) *	2002-11-27	2006-03-01	因塞特公司	作为趋化因子受体调节剂的3－氨基吡咯烷衍生物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002505684A (ja)	1997-06-18	2002-02-19	メルクエンドカンパニーインコーポレーテッド	α１ａアドレナリン受容体拮抗薬
US6037354A (en) *	1997-06-18	2000-03-14	Merck & Co., Inc.	Alpha 1a adrenergic receptor antagonists
AU4796700A (en) *	1999-05-13	2000-12-05	Dupont Pharmaceuticals Research Laboratories, Inc.	Ureido-substituted cyclic amine derivatives and their use as drug
CA2378499A1 (en)	1999-08-04	2001-02-15	Teijin Limited	Cyclic amine ccr3 antagonists
US6245799B1 (en) *	1999-11-08	2001-06-12	American Home Products Corp	[(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
JP2003513970A (ja)	1999-11-08	2003-04-15	ワイス	中枢神経系障害の治療のための［（インドール−３−イル）−シクロアルキル］−３−置換アゼチジン
EP1377625B1 (de) *	2001-03-26	2006-06-14	Bayer MaterialScience AG	Polycarbonat mit ausgeprägtem scherentzähungsverhalten
EP1565436B1 (en) *	2002-11-27	2012-04-25	Incyte Corporation	3-aminopyrrolidine derivatives as modulators of chemokine receptors
KR20080052683A (ko)	2003-12-18	2008-06-11	인사이트 코포레이션	케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
CN101065374A (zh) *	2004-09-28	2007-10-31	詹森药业有限公司	取代的二哌啶化学引诱物细胞因子受体2拮抗剂
PA8653301A1 (es) *	2004-11-22	2006-11-09	Incyte Corp Incyte Corp	Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
GB0513747D0 (en)	2005-07-06	2005-08-10	Merck Sharp & Dohme	Therapeutic compounds
US8067457B2 (en)	2005-11-01	2011-11-29	Millennium Pharmaceuticals, Inc.	Compounds useful as antagonists of CCR2
WO2007130712A1 (en)	2006-01-31	2007-11-15	Janssen Pharmaceutica, Nv	Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases
AR063275A1 (es) *	2006-10-12	2009-01-14	Epix Delaware Inc	Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
BRPI0820701A2 (pt) *	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
MX2011006226A (es) *	2008-12-10	2011-06-24	Janssen Pharmaceutica Nv	Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol del receptor 2 de citocina quimioatrayente.
TW201105649A (en) *	2009-04-16	2011-02-16	Janssen Pharmaceutica Nv	4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
CN102459226B (zh) *	2009-04-17	2014-09-17	詹森药业有限公司	Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
EP2419419B1 (en)	2009-04-17	2014-12-03	Janssen Pharmaceutica NV	4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2

2010
- 2010-04-15 EP EP10714804.1A patent/EP2419419B1/en active Active
- 2010-04-15 KR KR1020117026846A patent/KR20120006544A/ko not_active Withdrawn
- 2010-04-15 ES ES10714804.1T patent/ES2528625T3/es active Active
- 2010-04-15 CN CN201080027641.6A patent/CN102459227B/zh not_active Expired - Fee Related
- 2010-04-15 NZ NZ595432A patent/NZ595432A/en not_active IP Right Cessation
- 2010-04-15 US US12/761,080 patent/US20100267689A1/en not_active Abandoned
- 2010-04-15 MX MX2011010964A patent/MX2011010964A/es active IP Right Grant
- 2010-04-15 AU AU2010236346A patent/AU2010236346B2/en not_active Ceased
- 2010-04-15 JP JP2012506232A patent/JP5675773B2/ja not_active Expired - Fee Related
- 2010-04-15 WO PCT/US2010/031265 patent/WO2010121046A1/en not_active Ceased
- 2010-04-15 CA CA2758934A patent/CA2758934A1/en not_active Abandoned
- 2010-04-15 BR BRPI1016189A patent/BRPI1016189A2/pt not_active Application Discontinuation
- 2010-04-16 TW TW099111898A patent/TW201102377A/zh unknown
- 2010-04-19 AR ARP100101287A patent/AR076328A1/es unknown
2011
- 2011-10-25 US US13/280,690 patent/US8513229B2/en not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030004151A1 (en) *	2000-12-20	2003-01-02	Robert Cherney	Cyclic derivatives as modulators of chemokine receptor activity
CN1741994A (zh) *	2002-11-27	2006-03-01	因塞特公司	作为趋化因子受体调节剂的3－氨基吡咯烷衍生物

Also Published As

Publication number	Publication date
CA2758934A1 (en)	2010-10-21
US20120040960A1 (en)	2012-02-16
NZ595432A (en)	2013-12-20
US8513229B2 (en)	2013-08-20
TW201102377A (en)	2011-01-16
EP2419419A1 (en)	2012-02-22
MX2011010964A (es)	2011-11-02
JP2012524111A (ja)	2012-10-11
CN102459227A (zh)	2012-05-16
AR076328A1 (es)	2011-06-01
EP2419419B1 (en)	2014-12-03
JP5675773B2 (ja)	2015-02-25
BRPI1016189A2 (pt)	2016-04-19
KR20120006544A (ko)	2012-01-18
WO2010121046A1 (en)	2010-10-21
US20100267689A1 (en)	2010-10-21
AU2010236346A1 (en)	2011-11-03
ES2528625T3 (es)	2015-02-11
AU2010236346B2 (en)	2015-01-22

Legal Events

Date	Code	Title	Description
2012-05-16	C06	Publication
2012-05-16	PB01	Publication
2012-06-27	C10	Entry into substantive examination
2012-06-27	SE01	Entry into force of request for substantive examination
2012-07-11	C53	Correction of patent of invention or patent application
2012-07-11	CB03	Change of inventor or designer information	Inventor after: Zhang Xuqing Inventor after: Hufnagel Heather Inventor after: Hou Cuibin Inventor after: Johnson Dana L. Inventor after: Sui Zhihua Inventor before: Zhang Xuqing Inventor before: Hufnagel Heather Inventor before: C hou Inventor before: Johnson Dana L. Inventor before*: Sui Zhihua
2012-07-11	COR	Change of bibliographic data	Free format text: CORRECT: INVENTOR; FROM: ZHANG XUQING HUFNAGEL HEATHER HOU CULFEN JOHNSON DANA L. SUI ZHIHUA TO: ZHANG XUQING HUFNAGEL HEATHER HOU CUIBIN JOHNSON DANA L. SUI ZHIHUA
2014-08-20	C14	Grant of patent or utility model
2014-08-20	GR01	Patent grant
2019-04-05	CF01	Termination of patent right due to non-payment of annual fee
2019-04-05	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20140820 Termination date: 20180415

Publication	Publication Date	Title
CN102459227B (zh)	2014-08-20	Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
CN102459226B (zh)	2014-09-17	Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
CA2748251C (en)	2016-08-02	Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
CN102459225B (zh)	2014-08-20	Ccr2的4-氮杂环丁烷基-1-杂芳基-环己烷拮抗剂
ES2550312T3 (es)	2015-11-06	Antagonistas ciclohexil-azetidinilo de CCR2
JP6110474B2 (ja)	2017-04-05	Ｃｃｒ２の縮合シクロペンチル拮抗薬
SG171998A1 (en)	2011-07-28	4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
JP5530430B2 (ja)	2014-06-25	Ｃｃｒ２のピペリジルアクリルアミドアンタゴニスト
JP6204983B2 (ja)	2017-09-27	Ｃｃｒ２のオクタヒドロ−シクロペンタピロリル拮抗薬
EP2580208B1 (en)	2015-05-06	Cyclohexyl-azetidinyl antagonists of ccr2
CN103228644B (zh)	2016-06-01	Ccr2的4-取代-环己基氨基-4-哌啶基-乙酰胺拮抗剂
HK1162504B (en)	2018-03-09	Novel bicyclic heterocyclic compound